Exact Mass: 231.1079
Exact Mass Matches: 231.1079
Found 500 metabolites which its exact mass value is equals to given mass value 231.1079,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Aminophenazone
Aminophenazone is only found in individuals that have used or taken this drug. It is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of cytochrome P-450 metabolic activity in liver function tests. [PubChem]Aminophenazone is metabolized very slowly by normal newborn babies. In older infants, a higher amount of exhaled 13-CO2 is observed. N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BB - Pyrazolones C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic CONFIDENCE standard compound; EAWAG_UCHEM_ID 702 KEIO_ID A069; [MS3] KO008857 KEIO_ID A069; [MS2] KO008856 KEIO_ID A069
Fenfluramine
A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D049990 - Membrane Transport Modulators KEIO_ID F016; [MS2] KO009107 KEIO_ID F016
Butyrylcarnitine
Butyrylcarnitine, also known as (3R)-3-(butyryloxy)-4-(trimethylammonio)butanoate or L-carnitine butyryl ester, is classified as a member of the acylcarnitines. Acylcarnitines are organic compounds containing a fatty acid with the carboxylic acid attached to carnitine through an ester bond. Butyrylcarnitine is considered to be practically insoluble (in water) and acidic. Butyrylcarnitine is elevated in patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency, in infants with acute acidosis and generalized muscle weakness, and in middle-aged patients with chronic myopathy localized in muscle (OMIM: 201470). Butyrylcarnitine is elevated in patients with acyl-coa dehydrogenase, short-chain (SCAD) deficiencyin; in infants with acute acidosis and generalized muscle weakness; and in middle-aged patients with chronic myopathy localized in muscle. (OMIM 201470) [HMDB] Butyrylcarnitine is a metabolite in plasma, acts as a biomarker to improve the diagnosis and prognosis of heart failure, and is indicative of anomalous lipid and energy metabolism.
(S)-2-acetamido-6-oxopimelic acid
(S)-2-acetamido-6-oxopimelic acid is an oxo dicarboxylic acid, a N-acyl-amino acid and a dicarboxylic fatty acid. It is functionally related to a (S)-2-amino-6-oxopimelic acid. It is a conjugate acid of a (S)-2-acetamido-6-oxopimelate(2-).
N2-Succinyl-L-glutamic acid 5-semialdehyde
N2-Succinyl-L-glutamic acid 5-semialdehyde is a substrate for Succinate semialdehyde dehydrogenase (mitochondrial) and Ornithine aminotransferase (mitochondrial). It can be found in Escherichia (UniProt). N2-Succinyl-L-glutamic acid 5-semialdehyde is a substrate for Succinate semialdehyde dehydrogenase (mitochondrial) and Ornithine aminotransferase (mitochondrial). [HMDB]
Indeloxazine
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants Same as: D08077
TRIAZIQUONE
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AC - Ethylene imines C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D009676 - Noxae > D000477 - Alkylating Agents D000970 - Antineoplastic Agents
4-Formamidoantipyrine
A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a formaylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It is a metabolite of aminophenazone. CONFIDENCE standard compound; INTERNAL_ID 2701 CONFIDENCE standard compound; INTERNAL_ID 4113 CONFIDENCE standard compound; EAWAG_UCHEM_ID 1038 CONFIDENCE standard compound; INTERNAL_ID 2006
Isocarboxazid
Isocarboxazid is only found in individuals that have used or taken this drug. It is an MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311). Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors. N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AF - Monoamine oxidase inhibitors, non-selective D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors C471 - Enzyme Inhibitor > C667 - Monoamine Oxidase Inhibitor
Dexfenfluramine
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D049990 - Membrane Transport Modulators
Isobutyrylcarnitine (C4)
Isobutyryl-L-carnitine is an acylcarnitine. More specifically, it is an isobutyric acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Isobutyryl-L-carnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine isobutyryl-L-carnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular isobutyryl-L-carnitine is elevated in the blood or plasma of individuals with isobutyryl-coa dehydrogenase deficiency (PMID: 20591710), glutaric aciduria type 2 (PMID: 20591710), ethylmalonic encephalopathy (PMID: 20591710), and gestational diabetes mellitus (PMID: 29626588). It is also decreased in the blood or plasma of individuals with traumatic brain injury (PMID: 23560894). Isobutyryl-L-carnitine is elevated in the urine of individuals with glutaric aciduria type 2 (PMID: 2288224), multiple acyl-CoA dehydrogenation deficiency (PMID: 3383426), and acute coronary syndrome (PMID: 30316136). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. Isobutyryl-L-carnitine is a product of the acyl-CoA dehydrogenases (ACADs), which are a group of mitochondrial enzymes involved in the metabolism of fatty acids or branched-chain amino acids. (OMIM 600301 ) [HMDB] Isobutyrylcarnitine. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=25518-49-4 (retrieved 2024-06-29) (CAS RN: 25518-49-4). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
1-(m-Methoxycinnamoyl)pyrrolidine
1-(m-Methoxycinnamoyl)pyrrolidine is found in beverages. 1-(m-Methoxycinnamoyl)pyrrolidine is an alkaloid from the roots of kava (Piper methysticum). FDA advises against use of kava in food due to potential risk of severe liver damage (2002). Alkaloid from the roots of kava (Piper methysticum). FDA advises against use of kava in food due to potential risk of severe liver damage (2002). 1-(m-Methoxycinnamoyl)pyrrolidine is found in beverages.
Glycyl-Arginine
Glycyl-Arginine is a dipeptide composed of glycine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Asparaginyl-Valine
Asparaginyl-Valine is a dipeptide composed of asparagine and valine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Valylasparagine
Valylasparagine is a dipeptide composed of valine and asparagine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
Isovalerylglutamic acid
Isovalerylglutamic acid is an unusual mtabolite that has been found in the urine of patients with Isovaleric Acidemia due to Isovaleryl-CoA Dehydrogenase Deficiency (OMMBID: The Metabolic and Molecular Bases of Inherited Disease, Ch.93: Branched Chain Organic Acidurias). and in Multiple acyl-Co A dehydrogenation deficiency (MADD) (PMID 6862997). Isovalerylglutamate is a biomarker for the consumption of cheese. Isovalerylglutamic acid is an unusual mtabolite that has been found in the urine of patients with Isovaleric Acidemia due to Isovaleryl-CoA Dehydrogenase Deficiency (OMMBID: The Metabolic and Molecular Bases of Inherited Disease, Ch.93: Branched Chain Organic Acidurias)
Suberylglycine
Suberylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. However, the excretion of certain acyl glycines is increased in several inborn errors of metabolism. In certain cases the measurement of these metabolites in body fluids can be used to diagnose disorders associated with mitochondrial fatty acid beta-oxidation. Acyl glycines are produced through the action of glycine N-acyltransferase (EC 2.3.1.13) which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine < -- > CoA + N-acylglycineSuberylglycine is a dicarboxylic acid. It is formed by glycine-N-acylase catalyzed conjugation (PMID 947635). It can be used for the diagnosis of hereditary medium-chain acyl-CoA dehydrogenase deficiency (PMID 2775902). Suberylglycine is found to be associated with propionic acidemia, which is an inborn error of metabolism. Suberylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. However, the excretion of certain acyl glycines is increased in several inborn errors of metabolism. In certain cases the measurement of these metabolites in body fluids can be used to diagnose disorders associated with mitochondrial fatty acid beta-oxidation. Acyl glycines are produced through the action of glycine N-acyltransferase (EC 2.3.1.13) which is an enzyme that catalyzes the chemical reaction:
Arginylglycine
Arginylglycine is a dipeptide composed of arginine and glycine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.
(+/-)-(E)-Methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexeneamide
4-Formylaminoantipyrine
(2S)-2-Amino-7-(1-aminoethylideneamino)-5-sulfanylideneheptanoic acid
L-Proline, 1-(2-methyl-3-(methylthio)-1-oxopropyl)-, (S)-
indole-3-acetyl-glycine
Indole-3-acetyl-glycine is also known as iaa-gly. Indole-3-acetyl-glycine is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Indole-3-acetyl-glycine can be found in a number of food items such as pistachio, red rice, star anise, and redcurrant, which makes indole-3-acetyl-glycine a potential biomarker for the consumption of these food products.
Piperlotine A
Piperlotine A is a natural product found in Piper lolot and Piper sarmentosum with data available.
7-DIETHYLAMINO-4-METHYLCOUMARIN
CONFIDENCE standard compound; INTERNAL_ID 432; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9213; ORIGINAL_PRECURSOR_SCAN_NO 9212 CONFIDENCE standard compound; INTERNAL_ID 432; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9233; ORIGINAL_PRECURSOR_SCAN_NO 9232 CONFIDENCE standard compound; INTERNAL_ID 432; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9257; ORIGINAL_PRECURSOR_SCAN_NO 9255 CONFIDENCE standard compound; INTERNAL_ID 432; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9269; ORIGINAL_PRECURSOR_SCAN_NO 9268 CONFIDENCE standard compound; INTERNAL_ID 432; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9251; ORIGINAL_PRECURSOR_SCAN_NO 9250 CONFIDENCE standard compound; INTERNAL_ID 432; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9278; ORIGINAL_PRECURSOR_SCAN_NO 9276 CONFIDENCE standard compound; INTERNAL_ID 2483 CONFIDENCE standard compound; INTERNAL_ID 64 CONFIDENCE standard compound; INTERNAL_ID 8843
O-isobutyrylcarnitine
An O-acylcarnitine having isobutyryl as the acyl substituent.
(E)-3-(4-methoxyphenyl)-1-pyrrolidin-1-ylprop-2-en-1-one
Me glycoside,N-Ac,N-Me-alpha-D-Pyranose-4-Amino-2,4,6-trideoxy-3-O-methyl-ribo-hexose
Acetic acid [2-methyl-4-oxoquinolin-1(4H)-yl]methyl ester
bruceolline I
An indole alkaloid that is 1,2,3,4-tetrahydrocyclopenta[b]indole substituted by hydroxy groups at positions 2 and 6, geminal-methyl groups at position 3 and an oxo group at position 1. It has been isolated from the ethanol extract of the stems of Brucea mollis.
3-(2-acetyl-1H-pyrrol-1-yl)-5-(prop-2-yn-1-yl)dihydrofuran-2(3H)-one|longanlactone
3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihydropyridin-2(1h)-one
(7S)-5,6-dihydro-4-[(1R)-1-hydroxyethyl]-5H-spiro[cyclopenta[c]pyridine-7,2-furan]-5-one|plumericidine
fenfluramine
A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D049990 - Membrane Transport Modulators CONFIDENCE Parent Substance with Reference Standard (Level 1); INTERNAL_ID 600 CONFIDENCE standard compound; INTERNAL_ID 2248
Aminopyrine
N - Nervous system > N02 - Analgesics > N02B - Other analgesics and antipyretics > N02BB - Pyrazolones C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3407; ORIGINAL_PRECURSOR_SCAN_NO 3405 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3425; ORIGINAL_PRECURSOR_SCAN_NO 3421 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3402; ORIGINAL_PRECURSOR_SCAN_NO 3401 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3417; ORIGINAL_PRECURSOR_SCAN_NO 3413 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3416; ORIGINAL_PRECURSOR_SCAN_NO 3413 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3412; ORIGINAL_PRECURSOR_SCAN_NO 3409 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4497; ORIGINAL_PRECURSOR_SCAN_NO 4496 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4515; ORIGINAL_PRECURSOR_SCAN_NO 4514 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4531; ORIGINAL_PRECURSOR_SCAN_NO 4530 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4525; ORIGINAL_PRECURSOR_SCAN_NO 4523 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4544; ORIGINAL_PRECURSOR_SCAN_NO 4542 CONFIDENCE standard compound; INTERNAL_ID 663; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4527; ORIGINAL_PRECURSOR_SCAN_NO 4526 CONFIDENCE standard compound; INTERNAL_ID 2776 CONFIDENCE standard compound; INTERNAL_ID 4104
methyl 2-[(2-hydroxy-3-methylbutanoyl)amino]-3-methylbutanoate
2-[(2-hydroxy-3-methylbutanoyl)amino]-4-methylpentanoic acid
C14H17NO2_(2E)-3-(4-Methoxyphenyl)-1-(1-pyrrolidinyl)-2-propen-1-one
2-[(2-hydroxy-3-methylbutanoyl)amino]-4-methylpentanoic acid
Dexfenfluramine
A - Alimentary tract and metabolism > A08 - Antiobesity preparations, excl. diet products > A08A - Antiobesity preparations, excl. diet products > A08AA - Centrally acting antiobesity products D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
isocarboxazid
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AF - Monoamine oxidase inhibitors, non-selective D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors C471 - Enzyme Inhibitor > C667 - Monoamine Oxidase Inhibitor
methyl 2-[(2-hydroxy-3-methylbutanoyl)amino]-3-methylbutanoate [IIN-based on: CCMSLIB00000845070]
methyl 2-[(2-hydroxy-3-methylbutanoyl)amino]-3-methylbutanoate [IIN-based: Match]
2-[(2-hydroxy-3-methylbutanoyl)amino]-4-methylpentanoic acid_major
2-methoxy-5-methyl-N-phenyl-1H-imidazole-4-carboxamide
N-ETHOXYCARBONYLMETHYL-N’-CYANO-N-PHENYLFORMAMIDINE
4(3H)-Pteridinone,2-amino-5,6,7,8-tetrahydro-6,7-dimethyl-, hydrochloride (1:1)
3-(2-methylphenyl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione
4-(2,5-DIMETHYL-1H-PYRROL-1-YL)-2-HYDROXYBENZOIC ACID
methyl 1-benzyl-3,6-dihydro-2H-pyridine-5-carboxylate
4-ISOXAZOLECARBOXYLIC ACID, 3-METHYL-5-PHENYL-, ETHYL ESTER
4-(2-methoxyethoxy)pyridine-2-carboximidamide,hydrochloride
(R)-N-Boc-2,2-Dimethyl-4-hydroxymethyloxazolindine
4-(Mercaptomethyl)-1-piperidinecarboxylic acid tert-butyl ester
(3S,4S)-TERT-BUTYL 3-HYDROXY-4-(HYDROXYMETHYL)PIPERIDINE-1-CARBOXYLATE
3-AMINO-3-(2,6-DIFLUORO-3-METHOXY-PHENYL)-PROPIONIC ACID
3-AMINO-3-(2,6-DIFLUORO-4-METHOXY-PHENYL)-PROPIONIC ACID
3-AMINO-3-(2-DIFLUOROMETHOXYPHENYL)-PROPIONIC ACID
3-AMINO-3-(4-DIFLUOROMETHOXY-PHENYL)-PROPIONIC ACID
(2-[4-BENZYL-PIPERAZIN-1-YL]-2-OXO-ETHYL)-CARBAMICACIDTERT-BUTYLESTER
(S)-2-ACETAMIDO-4-(TERT-BUTOXY)-4-OXOBUTANOIC ACID
1H-Benzimidazole,5-methoxy-2-(4-piperidinyl)-(9CI)
3-(Piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one
METHYL 4-HYDROXY-7,8-DIMETHYLQUINOLINE-2-CARBOXYLATE
3-((TERT-BUTOXYCARBONYL)AMINO)TETRAHYDROFURAN-3-CARBOXYLIC ACID
2-[(1,3-dimethyl-1H-pyrazol-5-yl)amino]Benzoic acid
(2S,3R)-1-(TERT-BUTOXYCARBONYL)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID
2-Aminomethyl-5-phenyl-furan-3-carboxylic acid methyl ester hydrochloride
6-(methylamino)hexane-1,2,3,4,5-pentol,hydrochloride
2-Methyl-2-Propanyl 4-Hydroxy-4-(Hydroxymethyl)-1-Piperidinecarboxylate
6-AMINO-1-BENZYL-3-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE
Flumexadol
Flumexadol is a selective and affinity 5-HT2C receptor agonist with a Ki of 25 nM for the (+)-enantiomer of Flumexadol, and is 40-fold selective over the 5-HT2A receptor. Flumexadol is an orally active non-narcotic analgesic[1][2].
(R)-1-(5-(Trifluoromethyl)pyridin-2-yl)pyrrolidin-3-amine
4-(3-Isopropyl-1,2,4-oxadiazol-5-yl)piperidine hydrochloride
(2-amino-4,5-dimethylthiophen-3-yl)-phenylmethanone
4-METHYL-BETA-STYRYLBORONIC ACID DIETHANOLAMINE ESTER
3,4-Dimethoxy-N-methylphenethylamine hydrochloride
2-Fluoro-N-methyl-6-phenoxybenzylamine hydrochloride,
4-[di(methyl)amino]-1,5-dimethyl-2-phenylpyrazol-3-one
6-(3-Furanyl)-2-methylpyridine-3-carboxylic acid ethyl ester
(2S,3S)-1-(TERT-BUTOXYCARBONYL)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID
2-Pyridinethiol,1,4-dihydro-4,4,6-trimethyl-1-phenyl-
5-[4-(1-METHYLETHYL)PHENYL]-3-ISOXAZOLECARBOXYLIC ACID
1,5-DIMETHYL-3-OXO-2-PHENYL-2,3-DIHYDRO-1H-PYRAZOLE-4-CARBALDEHYDE OXIME
2-(1-piperidylmethyl)cyclohexan-1-one hydrochloride
4-ALLYL-5-(3-METHYLPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL
3-(2,5-DIMETHYL-PYRROL-1-YL)-4-HYDROXY-BENZOIC ACID
2-(Piperidin-4-yl)-5-(pyrazin-2-yl)-1,3,4-oxadiazole
BENZYL 4-OXO-3,4-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE
1-Hydroxy-3-amino-5,7-dimethyladamantane hydrochloride
2-AMINO-6-ISOPROPYL-4-OXO-4H-CHROMENE-3-CARBALDEHYDE
7-ISOPROPYL-1H-INDOLE-2-CARBOXYLIC ACID ETHYL ESTER
5-ISOPROPYL-1H-INDOLE-2-CARBOXYLIC ACID ETHYL ESTER
[1,1-biphenyl]-2-ol, compound with 2-aminoethanol (1:1)
Methyl 1-Benzyl-1,2,3,6-tetrahydropyridine-4-carboxylate
1-[1-(4-Methoxy-benzyl)-1H-[1,2,3]triazol-4-yl]-ethanone
2-Propenoic acid,2-cyano-3-(4-methoxyphenyl)-, ethyl ester
4-(2,3-EPOXYPROPOXY)-2-METHYL-1(2H)-ISOQUINOLINONE
2-Naphthalenecarboxamide,3-hydroxy-N-(2-hydroxyethyl)-
3-HYDROXYMETHYL-1(2H)-PYRIDINECARBOXYLIC ACID, PHENYL ESTER
2-[[2-[(dimethylamino)methyl]-1,3-thiazol-4-yl]methylsulfanyl]ethanamine
1-isopropyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
5-(2,5-DIMETHYL-PYRROL-1-YL)-2-HYDROXY-BENZOIC ACID
Ala-Ala-Ala
A tripeptide composed of three L-alanine units joined by peptide linkages.
4-(3,5-dimethyl-1,2-oxazol-4-yl)-3-methylbenzoic acid
tert-butyl N-(5-chloro-2-methylpyrazol-3-yl)carbamate
3-Quinolinecarboxylicacid, 6-methoxy-, ethyl ester
2-AMINO-6,7-DIMETHYL-4-HYDROXY-5,6,7,8-TETRAHYDROPTERIDINE MONOHYDROCHLORIDE
1-[(3-amino-4-quinolinyl)amino]-2-methyl-2-propanol
Glycine, N-[(1,1-diMethylethoxy)carbonyl]-N-(2-oxoethyl)-Methyl ester
3-(4-HYDROXY-2-METHYL-QUINOLIN-3-YL)-PROPIONIC ACID
2-[(2,2-DIMETHYL-4-OXO-3,4-DIHYDRO-2H-CHROMEN-7-YL)OXY]ACETONITRILE
Methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate
2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)acetonitrile
morpholine-3,4-dicarboxylic acid 4-tert-butyl ester
4-(4-Fluorobenzoyl)-1-methyl-1H-pyrrole-2-carbaldehyde
3-AMINO-3-(2-HYDROXY-NAPHTHALEN-1-YL)-PROPIONIC ACID
alpha-[1-[(2-Hydroxyethyl)Amino]Ethyl]Benzyl Alcohol Hydrochloride
Farampator
C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Farampator (CX-691;Org24448) is an AMPA receptor positive modulator.
N(2)-succinyl-L-ornithinate(1-)
A dicarboxylic acid monoanion that is the conjugate base of N(2)-succinyl-L-ornithine.
(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]propanoic acid
levofenfluramine
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
Glycine, N-(3-methyl-1-oxobutyl)-, trimethylsilyl ester
Indeloxazine
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants Same as: D08077
4-(L-gamma-glutamylamino)Butanoate
Conjugate base of 4-(L-gamma-glutamylamino)butanoic acid.
Nalidixic acid anion
A monocarboxylic acid anion that is the conjugate base of nalidixic acid; major species at pH 7.3.
4-(5,5-Dimethylcyclohex-1-en-1-yl)cyclohexa-1,3-diene-1-carboxylic acid
2-Amino-3-cyano-5,6,7,8-tetrahydroquinoline-4-carboxylic acid methyl ester
4-Methyl-2-[(5-methyl-2-thiophenyl)methylideneamino]phenol
2-[[2-Amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid
1-Spiro[2,4-dihydroisoquinoline-3,1-cyclohexane]thione
2-(4-methoxyphenyl)-N-(1,2,4-triazol-4-yl)ethanimidamide
(2R)-1-(3-mercapto-2,2-dimethyl-1-oxopropyl)-2-pyrrolidinecarboxylic acid
N-(2-aminoethyl)ethane-1,2-diamine;2-(chloromethyl)oxirane;hydrochloride
(3E)-5-methyl-3-[(N-methylanilino)methylidene]thiophen-2-one
3-amino-7-methoxy-5H-pyrimido[5,4-b]indol-1-ium-4-one
Methyl 5-ethyl-2-phenyl-1-pyrroline-4-carboxylate (4,5-cis)
N-(3,3-Dideutero-3-phenylpropionyl)piperidin-2-one
N-(2,2-Dideutero-3-phenylpropionyl)piperidin-2-one
N-(2,2,3,3-Tetradeutero-3-phenylpropionyl)piperidin-2-one
3-Methyl-6-nitro-1,2,3,4-tetrahydro-gamma-carboline
3-Methyl-8-nitro-1,2,3,4-tetrahydro-gamma-carboline
Methyl 2,3-dimethyl-5-phenyl-1-pyrroline-4-carboxylate (3,4-trans-4,5-cis)
Methyl 2,ref.-4-dimethyl-trans-5-phenyl-1-pyrroline-4-carboxylate
TRIAZIQUONE
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AC - Ethylene imines C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D009676 - Noxae > D000477 - Alkylating Agents D000970 - Antineoplastic Agents
L-Proline, 1-(2-methyl-3-(methylthio)-1-oxopropyl)-, (S)-
N-succinyl-L-glutamic 5-semialdehyde
A dicarboxylic acid monoamide obtained by the formal condensation of amino group of L-glutamic 5-semialdehyde with one of the carboxy groups of succinic acid.
AGN 192836
AGN 192836 is a potent and selective α2 adrenergic agonist with EC50s of 8.7, 41 and 6.6 nM for α2A, α2B and α2C receptor, respectively.
α7 Nicotinic receptor agonist-1
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder)[1].
